Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998054 | 0.91 | F10 (0.52) | F10 | |
| SCHEMBL5217193 | 0.91 | F10 (0.40) | F10ITGA4CNR1CNR2GAA | |
| SCHEMBL5504063 | 0.84 | F10 (0.42) | F10CNR1CNR2GAA | |
| SCHEMBL5206095 | 0.84 | F10 (0.54) | F10 | |
| SCHEMBL5506356 | 0.83 | F10 (0.41) | F10CNR1CNR2GAA | |
| SCHEMBL5515679 | 0.83 | F10 (0.58) | F10 | |
| SCHEMBL5518249 | 0.81 | F10 (0.42) | F10CNR1CNR2GAA | |
| SCHEMBL5212485 | 0.81 | F10 (0.54) | F10CNR1CNR2 | |
| SCHEMBL5513705 | 0.81 | F10 (0.54) | F10CNR1CNR2 | |
| SCHEMBL4461010 | 0.80 | F10 (0.41) | F10ITGA4CNR1CNR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005962-A1 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20100317848-A1 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317848-A1 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7476663-B2 | Substituted thiophene carboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| WO-2008080891-A2 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-10 | — | — | WO | disclosed |
| US-20050277628-A1 | Substituted thiophene carboxamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005962-A1 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | GART, DDC, ALDH7A1 | F10 1005/4885ITGA4 2332/4885CNR1 2851/4885 |
| US-20050277628-A1 | Substituted thiophene carboxamides | OTC, SLC22A8, DDC | F10 2132/4885ITGA4 4149/4885CNR1 1365/4885 |
| US-20100317848-A1 | PROCESS FOR THE SYNTHESIS OF DERIVATIVES OF 3-AMINO-TETRAHYDROFURAN-3-CARBOXYLIC ACID AND USE THEREOF AS MEDICAMENTS | GART, DDC, ALDH7A1 | F10 1040/4885ITGA4 2501/4885CNR1 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.